Chairman Griffith Delivers Opening Statement at Subcommittee on Health Legislative Hearing on Policies Protecting Communities from Emerging Illicit Drug Threats
Apnimed Announces Strategic Monetization of Shionogi-Apnimed Sleep Science (SASS) Joint Venture Stake for $150M and Royalties, Strengthening Focus on its Wholly-Owned OSA Program, AD109